Suppr超能文献

经尿道微波热疗治疗良性前列腺增生:疗效的持久性

Transurethral microwave thermotherapy for management of benign prostatic hyperplasia: durability of response.

作者信息

Baba S, Nakamura K, Tachibana M, Murai M

机构信息

Department of Urology, Keio University School of Medicine, Tokyo, Japan.

出版信息

Urology. 1996 May;47(5):664-71. doi: 10.1016/s0090-4295(96)00012-x.

Abstract

OBJECTIVES

The durability of clinical efficacy of transurethral microwave thermotherapy (TUMT) by Prostatron using a low-energy protocol (maximum power, 50 W) was evaluated on an outpatient basis in patients with symptomatic benign prostatic hyperplasia (BPH).

METHODS

One hundred eighteen patients were followed up for longer than 3 months (13.4 +/- 9.5 months; mean +/- SD). All evaluations were made at baseline and then 3, 6, 12, 24, and 36 months after therapy.

RESULTS

International Prostate Symptom Score (IPSS) significantly decreased from 18.2 to 10.6 at 6 months (P < 0.01), representing a mean improvement of 41% under the baseline. Peak flow rate increased from the baseline of 8.3 mL/s to 10.3 mL/s at 6 months (P < 0.01). The improvement in terms of mean values of both parameters was sustained up to 24 months. Six of 44 patients (14%) who were followed up for 31 months on average required transurethral resection of the prostate for recurring obstructive symptoms and 10 additional patients (23%) had to be treated with various drug regimens. When the clinical outcome was evaluated in terms of improvement from the baseline according to a response criteria, disease-free rates for IPSS (more than 25% improvement from the baseline) were 76% at 12 months, 77% at 24 months, and 61% at 36 months. Disease-free rate for peak flow rate (more than 2.5 mL/s from the baseline) was sustained in 44% by 12 months and in 48% by 24 months. The overall outcome of the treatment was assessed by adding scores based on both subjective and objective efficacy criteria. At 6 months, 67% of the patients were responders, and 15 of 21 (71%) remained as responders at 24 months. Patients who had estimated prostate volume smaller than 30 cc showed more marked improvement in peak flow rate (P < 0.02), and those with baseline IPSS of 20 or more showed greater reduction of IPSS (P < 0.05) at 24 months compared with each counterpart.

CONCLUSIONS

After TUMT with a low-energy protocol, satisfactory results were obtained and the improvement seems to last at least for 24 months. This low-energy protocol may be most beneficial in patients with relatively small size of the prostate.

摘要

目的

在门诊对有症状的良性前列腺增生(BPH)患者采用低能量方案(最大功率50W)的Prostatron经尿道微波热疗(TUMT)的临床疗效持久性进行评估。

方法

118例患者随访时间超过3个月(13.4±9.5个月;均值±标准差)。所有评估均在基线时以及治疗后3、6、12、24和36个月进行。

结果

国际前列腺症状评分(IPSS)在6个月时从18.2显著降至10.6(P<0.01),较基线平均改善41%。峰值尿流率在6个月时从基线的8.3mL/s增至10.3mL/s(P<0.01)。这两个参数均值的改善持续至24个月。44例平均随访31个月的患者中有6例(14%)因复发性梗阻症状需要行经尿道前列腺切除术,另有10例患者(23%)必须接受各种药物治疗。根据反应标准以较基线的改善情况评估临床结局时,IPSS的无病率(较基线改善超过25%)在12个月时为76%,24个月时为77%,36个月时为61%。峰值尿流率的无病率(较基线增加超过2.5mL/s)在12个月时维持在44%,24个月时维持在48%。根据主观和客观疗效标准加分评估治疗的总体结局。6个月时,67%的患者有反应,21例中有15例(71%)在24个月时仍有反应。前列腺估计体积小于30cc的患者峰值尿流率改善更明显(P<0.02),与各自对照组相比,基线IPSS为20或更高的患者在24个月时IPSS降低更显著(P<0.05)。

结论

采用低能量方案进行TUMT后,获得了满意的结果,且改善似乎至少持续24个月。这种低能量方案可能对前列腺体积相对较小的患者最为有益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验